KLOW Blend
GHK-Cu 50 mg · BPC-157 10 mg · TB-500 10 mg · KPV 10 mg
The four-peptide 'repair stack' — component science real, blend science absent
KLOW is not a single molecule but a fixed-ratio blend of four peptides that dominate the tissue-repair conversation: copper-binding GHK-Cu, the gastric pentadecapeptide BPC-157, the thymosin-β4 fragment TB-500, and the anti-inflammatory tripeptide KPV. Each component has its own preclinical literature pointing at a different piece of the repair process — matrix remodeling, cytoprotection, cell migration, and inflammation control. The blend itself is a community invention: the combination has never been studied together.
Looking to source KLOW Blend? It's stocked at RGP Labs — code KLOW10 applies automatically at checkout.
View KLOW Blend →A blend is a bet on synergy — and that bet is untested
The rationale behind KLOW is mechanistic plausibility: four peptides acting on complementary repair pathways should, in theory, do more together. It's a reasonable hypothesis, and it's why 'GLOW'-style stacks (this one adds KPV — the K) swept the skin and recovery communities. But no published study has tested these four together, at this ratio or any other. Everything below is component-level evidence; the synergy claim itself rests on zero data.
What the Research Actually Says
Every claim below is cited to the published literature and labeled by how far the evidence has actually progressed. Numbers refer to the reference list at the bottom of the page.
GHK-Cu — skin & matrix remodeling
Preclinical (cell & animal)The blend's dominant component by mass. GHK-Cu is a naturally occurring copper-binding tripeptide shown in laboratory models to stimulate collagen and glycosaminoglycan synthesis, modulate metalloproteinases, and shift gene expression toward regeneration — the backbone of its long history in skin-repair research.
BPC-157 — cytoprotection & soft-tissue repair
Preclinical (cell & animal)In rodent injury models spanning tendon, ligament, muscle, and gut, BPC-157 has been repeatedly associated with faster, more organized healing, with in vitro work pointing to enhanced fibroblast migration and VEGFR2-linked angiogenesis. No human RCTs exist.
TB-500 — actin regulation & cell migration
Early human trialsTB-500 is the synthetic fragment of thymosin β4, the body's main actin-sequestering peptide. Tβ4 promoted cell migration and wound repair in preclinical models and — unusually for this space — has been through early human wound-healing trials.
KPV — inflammation control
Preclinical (cell & animal)KPV is the C-terminal tripeptide of α-MSH and appears to carry much of the parent hormone's anti-inflammatory activity without its pigmentation signaling. In cell and rodent colitis models, KPV taken up via the PepT1 transporter reduced NF-κB activation and inflammatory cytokine output.
Where the Evidence Stops
- ◆There are no published studies of the KLOW combination itself — not the four-way blend, not the ratio. Every claim about the blend is an extrapolation from single-compound studies.
- ◆The 50/10/10/10 ratio is a market convention, not the product of any dose-finding research. Note that GHK-Cu is over 60% of the vial.
- ◆Only one component (TB-500's parent molecule, thymosin β4) has been in human trials; BPC-157 and KPV evidence is entirely preclinical, and human data on GHK-Cu is mostly limited to topical cosmetic studies.
- ◆BPC-157 and TB-500 are prohibited in competitive sport under WADA rules — a blend containing them is too.
Research-grade KLOW Blend, batch-documented
RGP Labs ships from the US and publishes a batch number and full specifications for every vial. Code KLOW10 takes 10% off — applied automatically at checkout.
Sold for laboratory research use only — not for human consumption.
Transparency: Peptide Insights has a disclosed referral relationship with RGP Labs and may earn a commission on purchases made through links or codes on this page. That never changes the price you pay or what the research above says. See our FAQ and disclaimer.
Not ready to decide about KLOW Blend?
Our free guide covers KLOW Blend and nine other research peptides in depth — mechanisms, the state of the evidence, safety considerations, and a supplier-vetting checklist — across 12 chapters and 140+ citations.
References
- Pickart L, Margolina A Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences, 2018.
- Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 2011.
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 2011.
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy, 2012.
- Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 2008.
- Brzoska T, Luger TA, Maaser C, Abels C, Böhm M Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocrine Reviews, 2008.
Published 2026-08-17. Reviewed against the cited primary literature.
This page is for educational purposes only and is not medical advice. Peptides discussed here are research compounds; nothing here is a recommendation to use them. Consult a qualified healthcare provider about anything affecting your health.